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Abstracts
Gregory L. Moneta, MD, Section EditorAdherence to Mediterranean Diet and Risk of Coronary Heart Disease
in the Spanish EPIC Cohort Study
Buckland G, Gonzalez CA, Agudo A, et al. Am J Epidemiol 2009;170:
1518-29.
Conclusion: A Mediterranean diet is an effective method of primary
prevention for coronary heart disease.
Summary: There is an increase in longevity and a lower incidence of
vascular disease associated morbidity and mortality in southern compared
with northern Europe in the Seven Country Study and in the Monitoring of
Trends and Determinants in Cardiovascular Diseases (MONICA) survey
(Am J Epidemiol 1986;124:903-15 and Lancet 1999;353:1547-57). A
Mediterranean diet score as been developed to investigate the health effects
of Mediterranean diets. The key features of a Mediterranean diet are high
consumption of olive oil and plant-based foods, such as fruit, vegetables,
legumes, whole-grain cereals, nuts, and seeds, with moderate-to-high con-
sumption of fish, moderate consumption of alcohol (particularly red wine)
and dairy products, and relatively low consumption of meat (especially red
meat). The data suggest a 2-point increase in theMediterranean diet score is
associated with a 9% reduced risk of mortality from cardiovascular disease
(N Engl J Med 2003;343:2599-608).
Most studies in this field have been case-controlled studies that have
focused on individuals with known cardiovascular disease and have examined
secondary preventive effects of a Mediterranean diet. Nutritional factors
related to secondary prevention of vascular disease may not be the same as
those related to primary prevention. The purpose of this study was to
investigate, in a prospective fashion, the relationship between adherence to a
relative Mediterranean diet and incident coronary events, focusing on pri-
mary prevention. The study focused on patients from five Spanish centers of
the European Prospective Investigation into Cancer (EPIC) and Nutrition
Study. Data were analyzed from 41,078 participants aged 29 to 69 years
recruited from 1992 to 1996. They were followed-up until December 2004
for a median of 10.4 years. The incidence of fatal and nonfatal coronary heart
disease events was analyzed according to adherence to a Mediterranean diet.
This was measured by using an 18-unit relative Mediterranean diet score.
Of the study participants, 609 (79% male) had a confirmed fatal or
nonfatal acute myocardial infarction (n 468) or unstable angina requiring
revascularization (n  141). Adjusting for age, center, and recognized
coronary heart disease risk factors, a high compared with low relative
Mediterranean diet score was associated with a significant reduction in
coronary heart disease risk (hazard ratio, 0.6; 95% confidence interval,
0.47-0.77). A 1-unit increase in the relative Mediterranean diet score was
associated with a 6% reduced risk of coronary heart disease (95% confidence
interval, 0.91-0.97).
Comment:The results of this study add to the existing literature on the
health benefits of a Mediterranean diet by providing evidence of the impor-
tance of aMediterranean diet in the primary prevention of coronary events in
healthy individuals. Which components of the Mediterranean diet are most
important in providing primary cardioprotective effects are unknown. Sort-
ing out the individual effects of the Mediterranean diet, and whether the
health benefits also translate to the peripheral arteries, will likely be an
important future focus of this type of epidemiologic research.
Carotid Artery Stenting Compared with Endarterectomy in Patients
with Symptomatic Carotid Stenosis (International Carotid Stenting
Study): An Interim Analysis of a Randomised Controlled Trial
International Carotid Stenting Study Investigators. Lancet 2010;375:985-97.
Conclusion: In patients with symptomatic internal carotid artery
(ICA) stenosis who are suitable for surgery, carotid endarterectomy, at the
present time, should remain the treatment of choice.
Summary:Carotid artery stents have emerged as an alternative treatment
to endarterectomy for selected patients with asymptomatic and symptomatic
ICA stenosis. Previous randomized, controlled, government-sponsored trials
have failed to establish equivalency of the safety and efficacy of carotid artery
stenting to endarterectomy in symptomatic patients. Patients in the Stent-
Protected Angioplasty versus Carotid Endarterectomy trial (SPACE) did not
show noninferiority of stenting compared with endarterectomy within 30
days of treatment. The trial was stopped early for statistical reasons of futility
and for costs (Lancet 2006;368:1239-47). Another European trial, The
Endarterectomy versus Stenting in Patients with Symptomatic Severe Ca-
rotid Stenosis (EVA-3S) trial, was also stopped early because of higher
periprocedural stroke and death rates in the stenting group (N Engl
J Med 2006;355:1660-71).
1320In this study, the authors report results of the International Carotid
Stenting Study (ICSS). ICSS is a multicenter, international, randomized,
controlled trial of carotid endarterectomy vs stenting in patients with re-
cently symptomatic carotid artery stenosis. Recent symptomswere defined as
amaurosis fugax, transient ischemic attacks, ipsilateral hemispheric stroke, or
retinal infarction occurring within the previous year (95% of the patients in
the study were randomized within 6 months of their symptomatic event).
The study used blinded adjudication of outcomes, and patients were as-
signed in a randomized fashion to receive a 1:1 ratio of carotid artery
stenting or endarterectomy. Each center was stratified for sex, age, contralat-
eral occlusion, and side of randomized artery. Physicians not involved in the
randomized treatment provided the follow-up. The study is designed with a
primary end point of fatal or nondisabling stroke in any territory at 3 years.
The current article represents an interim safety analysis of 120-day rate of
stroke, death, or procedural myocardial infarction. Analysis was performed
on an intention-to-treat basis and on a per-protocol basis.
The trial enrolled 1713 patients, consisting of 858 in the endarterec-
tomy group and 855 in the stenting group. Between randomization and 120
days, there were 34 events of disabling stoke or death in the stenting group
(4% by Kaplan-Meier estimate) and 27 in the endarterectomy group (3.2%
by Kaplan-Meier estimate; hazard ratio [HR], 1.28; 95% confidence interval
[CI], 0.77-2.11). The occurrence of any stoke, death, or myocardial infarc-
tion in the stenting group was 8.5% vs 5.2% in the endarterectomy group (72
vs 44 events; HR, 1.69; 95% CI, 1.16-2.45; P  .006). Risk of any stroke
(65 vs 35 events; HR, 1.92; 95% CI, 1.27-2.89) and all cause death (19 vs 7
events; HR, 2.76; 95% CI, 1.16-6.56) were higher in the stenting group
than in the endarterectomy group. Of the seven peri-procedural myocardial
infarctions that were recorded, three were in the stenting group and all were
fatal; four were in the endarterectomy group, and none were fatal. There
were 45 cranial nerve palsies in the endarterectomy group and one in the
stenting group. There were 31 significant hematomas in the stenting group
vs 50 in the endarterectomy group (P  .0197).
Comment: This study was released online to coincide with presenta-
tion of the Carotid Revascularization Endarterectomy Versus Stenting Trial
(CREST) data at the recent stroke meetings in San Antonio. The CREST
manuscript at the time of this writing is currently under review and not
available for analysis. However, it is safe to say that the results of ICSS and
CREST, while conflicting in some respects, are similar in others. These
similarities and differences will provide fodder for comments and discussion
for a considerable period. All of us involved in the treatment of patients with
symptomatic carotid stenosis will have to evaluate the preponderance of data
that is available to help us decide how to treat our patients with symptomatic
carotid stenosis. Although it is quite clear that the European data taken as a
whole favor endarterectomy over stenting for patients with symptomatic
carotid stenosis, the differences in the short-term are not so great that
patients presented with options in an appropriate and unbiased manner can
reasonably choose either procedure. Physicians, however, must make rec-
ommendations, and it will be up to each treating physician to make respon-
sible recommendations to individual patients, independent of financial con-
siderations.
Carotid Endarterectomy Benefits Patients with CKD and Symptomatic
High-Grade Stenosis
Mathew A, Eliasziw M, Dvereaux PJ, et al; for the North American Symp-
tomatic Carotid Endarterectomy Trial (nascet) Collaborators. J Am Soc
Nephrol 2010;21:145-52.
Conclusion: Patients with stage 3 chronic kidney disease (CKD) and
symptomatic high-grade carotid stenosis have a marked benefit in stroke risk
reduction after carotid endarterectomy.
Summary: Approximately 800,000 people in North America have a
stroke each year, and nearly 200,000 of these are recurrent strokes (Circu-
lation 2009;119:e21-181). More than 15 million Americans have CKD,
with an increasing prevalence (JAMA 2007;298:2038-47). Patients with
CKD in some cases are more prone to adverse events complicating proce-
dures and treatments. In other situations, however, patients with CKD
derive larger absolute benefits because of higher baseline risk. The North
American Symptomatic Carotid Endarterectomy Trial (NASCET) collected
baseline levels of serum creatinine for all trial participants. The aim of this
study was to examine outcomes of patients with and without CKD enrolled
in NASCET.
Patients in this reanalysis included those with symptomatic stenosis and
either stage 3 CKD (n  524; estimated glomerular filtration rate [GFR]
260 mL/min/1.73 m ) or preserved kidney function (n  966; estimated
GFR60mL/min/1.73m2). GFR was determined using theModification
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medically treated patients’ risk with high-grade ICA stenosis (70%) for
ipsilateral stroke at 2 years was higher in patients with CKD then in those
with preserved renal function (31.6% vs 19.3%; P  .042). Carotid endar-
terectomy reduced this risk by 82% and 51%, respectively. Prevention of one
stroke in terms of numbers needed to treat was 10 for patients with preserved
renal function. However, the number needed to treat to prevent one stroke
was only four in patients with CKD. Patients with CKD had similar rates of
perioperative stroke and death but higher rates of perioperative cardiac
deaths than patients without CKD.
Comment: Twelve years after its initial publication, the NASCET trial
is still spinning off interesting—but very thinly sliced—additional pieces of
salami. Patients with CKD can be inappropriately denied interventions
because of perceived, but not proven, high risk. This phenomenon has been
termed “renalism” (J Am Soc Nephro 2004;15:246.2468). The article is
interesting because it not only reports patients with symptomatic high-grade
ICA stenosis and CKD appear to drive significant benefit from endarterec-
tomy but also raises the concept that patients with CKD, although at higher
risk with certain procedures, may actually, in the long-term, derive increased
benefit over those without CKD. Also, as the authors pointed out, large
randomized trials should consider enrolling, rather than somewhat arbi-
trarily excluding, patients with CKD. CKD patients may actually derive
unexpected and substantial benefit from selected procedures.
Collected World and Single Center Experience with Endovascular
Treatment of Ruptured Abdominal Aortic Aneurysms
Veith FJ, Lachat M, Mayer D, and the RAAA Investigators. Ann Surg
2009;250:818-24.
Conclusion: In some patients, endovascular repair of ruptured abdom-
inal aortic aneurysms (AAAs) has a lower procedural mortality at 30 days.
Summary: Endovascular aneurysm repair (EVAR) for ruptured AAA
was first reported in themid-1990s (Ann Surg 1995;222:449-65 and Lancet
1994;344:1645). Since then, EVAR for ruptured AAAs has been reported
with varying results. Some authors have concluded that EVAR results in
improved survival in patients with ruptured AAA, but others have reported
no better results with EVAR than traditional repair. Also, historic controls of
open repair results are often used to compare with modern results of EVAR.
All reports are case-series. There are no randomized trials comparing EVAR
and open repair in patients with similar anatomy and hemodynamic stability.
This article represents an attempt by the authors to summarize the
literature with respect to endovascular treatment of ruptured AAAs. The
authors examined a collective experience with use of EVAR to treat ruptured
AAAs from 49 centers. Each center provided data in the form of answers to a
questionnaire; in addition, a separate analysis was performed from 13 centers
committed to EVAR treatment for ruptured AAA whenever possible.
Information was obtained on 1037 patients treated by EVAR and 763
patients treated by open repair. In the 13 centers performing EVAR for
ruptured AAA whenever possible, EVAR was actually performed in a mean
of 49.1% of patients (range, 28%-79%). The 30-day mortality in 680 patients
treated with EVAR for ruptured AAA in these centers was 19.7% (range,
0%-32%). The 30-day mortality of the 763 patients treated with open repair
was 36.3% (range, 8%-53%; P 0.0001). Of the 1037 patients treated with
EVAR for ruptured AAA, 30-day mortality was 21.2%. In the 13 centers
using EVAR whenever possible, supraceliac aortic balloon control was
obtained in 19.1%  12%. An abdominal compartment syndrome was
treated by some form of decompression in 12.2%  8.3%.
Comment: One cannot argue with the conclusion EVAR has a lower
procedural mortality in “at least some patients” and may be preferable for
treating ruptured AAAs “provided that they (patients) have favorable anat-
omy; and adequate skills, facilities, and protocols are available, and optimal
strategies, techniques, and adjuncts are employed.” This is a classic “mom
and apple pie statement.” Whether or not it is correct or incorrect is actually
relatively unimportant. For the foreseeable future, individual surgeons will
need to make individual decisions for the treatment of ruptured AAA in
individual patients. I do not agree with Dr Veith that performing a random-
ized trial of open vs EVAR for treatment of matched patients with ruptured
AAA would be like performing a randomized trial on the use of parachutes.
I do agree with Dr Veith that such a trial would be difficult to perform and
that the performance of such a trial that provided results convincing to all
would be nearly impossible.
Efficacy of Aggressive Lipid Controlling Therapy for Preventing Sa-
phenous Vein Graft Disease
Hata M, Takayama T, Sezai A, et al. Ann Thorac Surg 2009;88:1440-4.
Conclusion: Aggressive lipid-controlling therapy may be effective in
preventing saphenous vein graft disease after coronary artery bypass grafting
(CABG).
Summary: About 25% of saphenous vein grafts occlude 1 year of
CABG, and 50% occlude  10 years (Am Heart J 1990;119:1164-84).
Despite their relative unfavorable natural history, saphenous vein grafts arestill used in70% of CABG procedures. It appears that plaque rupture with
thrombus formation are a major cause of long-term saphenous vein graft
disease after CABG (Circulation 2007;71:286-7). It also appears that low-
ering low-density lipoprotein cholesterol (LDL-C) 100 mg/dL may be
effective in reducing atherosclerosis in saphenous vein grafts. In this study,
the authors sought to investigate the efficacy of aggressive statin therapy on
angioscopic-determined progression of saphenous vein graft disease after
CABG.
There were 21 patients after CABG divided into two groups. Group I
comprised 10 patients whose serum LDL-C levels and LDL/high-density
lipoprotein (HDL) ratios could be controlled to 80 mg/dL and 1.5,
respectively. Group II consisted of 11 patients whose LDL-C levels and
LDL/HDL ratios were100mg/dL and2.5, respectively. Twenty-seven
saphenous vein grafts were assessed by intravascular ultrasound (IVUS) and
angioscopy at 12 to 16 months postoperatively.
Serum LDL-C levels in group I were 64.1 vs 130.2 mg/dL in group II.
LDL/HDL ratios in group I were 1.36 vs 2.64 in group II. High-sensitivity
C-reactive protein in group I was 0.045  0.1 vs 0.116  0.02 mg/dL in
group II. All values were significantly lower in group I. In group II, IVUS
detected eccentric plaques in 11 of 14 saphenous vein grafts (78.6%). Yellow
plaque was present in all 14 saphenous vein grafts by angioscopy, and 11 of
these grafts had thrombi. The 13 saphenous vein grafts in group I had no
eccentric or yellow plaques, and no thrombi were visible. The intima was
entirely clear white.
Comment: The mechanism of failure of saphenous vein grafts in the
coronary circulation may be different than that in the peripheral circulation.
However, the idea that driving down LDL-C and C-reactive protein levels
may improve vein graft patency is intriguing for the peripheral vascular
surgeon as well. Indeed, there is evidence suggesting higher primary assisted
and secondary patency in lower extremity vein grafts in patients treated with
statins (J Vasc Surg 2004;39:1178-85). Well-designed prospective data are
needed to assess the effects of statins on suppression of peripheral vein graft
lesions.
Randomized Comparison of Strategies for Type B Aortic Dissection:
The INvestigation of STEent Grafts in Aortic Dissection (INSTEAD)
Trial
Nienaber CA, Rousseau H, Eggebrecht H, et al. Circulation 2009;120;
2519-28.
Conclusion: In survivors of uncomplicated type B aortic dissection,
thoracic aortic stent grafts do not improve 2-year survival or adverse event
rates despite favorable aortic remodeling.
Summary: Thoracic endovascular aortic repair (TEVAR) was intro-
duced in 1999. The role of TEVAR in improving outcome in uncomplicated
type B aortic dissection is unknown. Stable patients undergoing medical
treatment with type B aortic dissection have an annual survival rate of80%;
however, aneurysm expansion and late complications do occur. Continued
perfusion of the false lumen is a risk factor for adverse outcomes, and
complete thrombosis of the false lumen has been associated with improved
outcome (Ann Thorac Surg 2007;83:1059-66 and Eur J Cardiothorac Surg
2004;26:359-66). The authors sought to determine whether placement of
thoracic aortic stent grafts might improve the prognosis in patients with
stable type B aortic dissection.
There were 140 patients who were clinically stable for at least 2 weeks
after an index type B aortic dissection. These patients were randomly
assigned to receive either elective stent graft placement in addition to
optimummedical therapy (n 72) or to optical medical therapy alone (n
68) with surveillance. Arterial pressure was treated according to World
Health Organization guidelines (attempting to achieve blood pressure of
120/80 mm Hg). All-cause death at 2 years was the primary end point.
Secondary end points were aortic-related deaths, progression (with need for
conversion or additional endovascular or open surgery), and aortic remod-
eling.
There was no difference in all-cause deaths between the two groups.
The 2-year cumulative survival was 95.6%  2.5% with optimum medical
therapy vs 88.9%  3.7% with TEVAR (P  .15). Aortic-related death rate
was not different (P  .44), and the risk for the combined end point of
aortic-related death (rupture) and progression (conversion or additional
endovascular or open surgery) was also similar (P  .65). There were three
adverse neurologic events in the TEVAR group and one patient with
transient paraparesis with medical treatment alone. Aortic remodeling (with
true lumen recovery and false-lumen thrombosis) occurred in 91.3% of
patients with TEVAR vs 19.4% of those who received medical treatment
alone (P  .004).
Comment: Uncomplicated type B aortic dissection managed with
tight blood pressure control and surveillance results in excellence survival
rates. At present, TEVAR can be considered an appropriate crossover
strategy if complications occur with a previously stable type B aortic dissec-
tion as, at least in this study, crossover patients uniformly survived deferred
TEVAR. The study supports, at least in the short-term, a complication-
specific approach to type B aortic dissection. Follow-up was relatively short
in this study, but even with short follow-up, favorable aortic remodeling
